Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 9:08 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1873–1896 of 4,345 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Time Management Clear all

Conditions: Selective Mutism
Interventions: Integrated behavioral therapy (BT); Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 4 Years to 8 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia (AML)
Interventions: Clofarabine; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 6
States / cities: Chicago, Illinois • New York, New York • Winston-Salem, North Carolina + 3 more

Conditions: Chronic Pain
Interventions: Hydrocodone ER; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 54
States / cities: Mobile, Alabama • Anaheim, California • Beverly Hills, California + 46 more

Conditions: Non-Hodgkin's Lymphoma
Interventions: [ 18F]F-AraG PET; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Stanford, California

Conditions: Solid Tumors, Lung Cancer
Interventions: BKM120, Everolimus; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Tobacco Use Disorder/Cigarette Smoking
Interventions: Multi-Theory Model (MTM)-Based Smoking Cessation Program; Behavioral
Lead sponsor: University of Nevada, Las Vegas; Other
Eligibility: 18 Years to 29 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Hematologic Malignancies
Interventions: Busulfan 3.2 mg/kg/day, Fludarabine, Melphalan, Antithymocyte globulin (ATG), Busulfan 0.8 mg/kg, Allogeneic hematopoietic cell transplantation (Allo-HCT); Drug · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Knee Osteoarthritis
Interventions: DoD/VA CPG Core Set + PT, DoD/VA CPG Core Set; Behavioral
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: 18 Years to 60 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 3
States / cities: San Antonio, Texas • Tacoma, Washington

Conditions: Healthy Volunteers
Interventions: AZD2373 subcutaneous injection, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Lymphoma, Non-Hodgkin
Interventions: Cyclophosphamide, BCNU, Etoposide, Filgrastim, Antithymocyte globulin, Cyclosporine, Mycophenolate mofetil, Rituximab, Autologous hematopoietic stem cell transplantation (auto-HSCT), Allogeneic hematopoietic stem cell transplantation (allo-HSCT), Total lymphoid irradiation, CD34+ Cells, Solu-Medrol; Drug · Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 1
States / cities: Stanford, California

Conditions: Surgery
Interventions: .9 normal saline placebo, Group L (lidocaine); Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Sleep
Interventions: Chilipad Dock Pro Bed Cooling System and Sleep Tracker; Device
Lead sponsor: Efforia, Inc; Industry
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Early Detection of Cancer, Lung Neoplasms
Interventions: EHR-integrated Shared Decision Making Tool and Clinical Decision Support for Lung Cancer Screening; Other
Lead sponsor: University of Utah; Other
Eligibility: 55 Years to 80 Years
Enrollment: 1,855 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Traumatic Subdural Hematoma
Interventions: Follow-up Care; Other
Lead sponsor: Tarik Wasfie, MD; Industry
Eligibility: 18 Years to 105 Years
Enrollment: 167 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Grand Blanc, Michigan

Conditions: Leber Congenital Amaurosis
Interventions: voretigene neparvovec-rzyl; Biological
Lead sponsor: Spark Therapeutics, Inc.; Industry
Eligibility: 8 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Chronic Interstitial Cystitis, Bladder Pain Syndrome, Cystitis, Interstitial, Painful Bladder Syndrome, Cystitis, Chronic Interstitial, Interstitial Cystitis, Interstitial Cystitis, Chronic, Interstitial Cystitis (Chronic) With Hematuria, Interstitial Cystitis (Chronic) Without Hematuria, Chronic Prostatitis, Chronic Prostatitis With Chronic Pelvic Pain Syndrome
Interventions: Psychosocial Treatment, Attention Control; Behavioral
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hepatitis C Virus (HCV), Hepatitis C Virus (HCV) Infection, HIV (Human Immunodeficiency Virus)
Interventions: Physician-Initiated Screening (Conventional Screening), FOCUS (Universal Screening), HepC-EnD (Targeted Screening); Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 79 Years
Enrollment: 6,466 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Gainesville, Florida • Jacksonville, Florida

Conditions: Depressive Symptoms
Interventions: Resiliency Class, Resource for Services (RS); Behavioral · Other
Lead sponsor: Bowen Chung, MD, MSHS; Other
Eligibility: 18 Years and older
Enrollment: 265 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 22
States / cities: Compton, California • Long Beach, California • Los Angeles, California + 1 more

Conditions: Contrast Allergies
Interventions: ERCP as medically indicated by subjects referring physician; Procedure
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Keratoconus, Corneal Ectasia
Interventions: Riboflavin; Drug
Lead sponsor: Cornea and Laser Eye Institute; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2025
U.S. locations: 1
States / cities: Teaneck, New Jersey

Conditions: SARS-CoV-2 Pneumonia, COVID-19
Interventions: Hydroxychloroquine; Drug
Lead sponsor: Kootenai Health; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Coeur d'Alene, Idaho

Conditions: Postpartum Depression, Postpartum Anxiety
Interventions: ROSE, Standard of Care; Behavioral · Other
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older · Female only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Acute Decompensated Heart Failure
Interventions: Reprieve System, furosemide infusion; Device · Drug
Lead sponsor: Reprieve Cardiovascular, Inc; Industry
Eligibility: 22 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 35
States / cities: Irvine, California • Long Beach, California • Sacramento, California + 28 more

Conditions: Dementia, Alzheimer Disease, Caregiver Stress
Interventions: Structured Retrieval Practice, Reading-Based Education; Behavioral
Lead sponsor: Virginia Wesleyan University; Other
Eligibility: 50 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Virginia Beach, Virginia

Search by objective public record fields.

Integrated Behavioral Therapy for Treating Children With Selective Mutism

A Dose Confirmation Study of Oral Clofarabine for Adult Patients Previously Treated for Myelodysplastic Syndromes (MDS)

Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) in Patients Who Require Opioid Treatment for an Extended Period of Time

18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma

A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies

Smoking Cessation Intervention for Young Adults Using MTM: A Randomized Controlled Trial

Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation

Non-Surgical Management of Knee Osteoarthritis in the Military Health System (MHS)

A Study to Assess Safety, Tolerability, PK and PD of AZD2373 in Healthy Male Participants of Sub-Saharan West African Ancestry

Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma

Lidocaine and Prevention of Chronic Pain

Chilipad Sleep Optimization Study

Evaluation of a Scalable Decision Support and Shared Decision Making Tool for Lung Cancer Screening

Factors Influencing Readmission Rates of Acute Traumatic Subdural Hematoma in the Elderly

Phase 1 Follow-on Study of AAV2-hRPE65v2 Vector in Subjects With Leber Congenital Amaurosis (LCA) 2

Optimizing Psychosocial Treatment of Interstitial Cystitis/Bladder Pain Syndrome

Assessing Performance of a Hepatitis C Emergency Department (HepC-EnD) Screening Tool: IT Integration Process for Electronic Health Record System

Resilience Against Depression Disparities (Also Known as Resilience Education to Reduce Depression Disparities)

Reactions to Contrast Media (CM) Administered at the Time of the Endoscopic Retrograde Cholangiopancreatography (ERCP)

Transepithelial Corneal Collagen Crosslinking for Keratoconus and Corneal Ectasia

Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia Trial

A Pilot Trial of the Reach Out, Stay Strong, Essentials for Mothers of Newborns (ROSE) Postpartum Depression Prevention Intervention in Pregnant Patients Admitted to Strong Hospital

Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)

Comparing Structured Retrieval Practice and Reading-Based Education for Dementia Caregivers